BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05778071 (Eneboparatide in Chronic Hypoparathyroidism): BVCT ex-ante prediction vs. reported outcome

On 12 Dec 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 17 Mar 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT05778071
Acronym
CALYPSO
Drug Name
Eneboparatide (AZP-3601)
Drug MoA
PTH1R agonist
Drug Modality
peptide
Drug Class
First-In-Class
Therapeutic Area
Endocrine System Diseases
Indication
Chronic Hypoparathyroidism (HypoPT)
Human Patients
165
Sponsor
AstraZeneca
Phase
Phase 3

Prediction of , index 1864

Prospective Prediction
Prediction Index
1864
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit in both supplement independence and hypercalciuria)
Technical Prediction
SUCCESS (statistically significant clinical benefit in the composite endpoint compared with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
95 days in advance
Readout Data Interpretation
eneboparatide has met the composite primary endpoint
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO)
Phase
Phase 3
Status
Active not recruiting
Enrollment
165
Lead sponsor
Alexion Pharmaceuticals, Inc.
Conditions
Chronic Hypoparathyroidism; Endocrine System Diseases; Parathyroid Diseases
Interventions
COMBINATION_PRODUCT: eneboparatide; COMBINATION_PRODUCT: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-06-07
Primary completion
2024-11-15
Completion
2027-06-16
Primary outcomes
  • Efficacy - Primary Endpoint (24 weeks)

NCT05778071 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials